Treatment of Psoriasis With Parathyroid Hormone

Status Completed

Clinical Trial Summary

This is a clinical study in two phases. The first phase compares the effect of an ointment containing parathyroid hormone (PTH) with the effect of a placebo ointment (inactive ointment without PTH) on psoriasis lesions. Neither the study participants nor the researchers will know who is receiving PTH ointment and who is receiving placebo until the end of this first study phase. The second phase is a study of the PTH ointment on large areas of psoriasis to find out how long the effects last.

Clinical Trial Description

Patients with active plaque psoriasis will be withdrawn from systemic and topical medications. After washout, we will select active psoriatic lesions of at least 25 square cm in size to receive either placebo ointment or a proprietary ointment containing PTH for 8 weeks. We will see the patients every 2 weeks. We will evaluate the lesions by examination and digital photography at each visit and measure parameters of calcium metabolism periodically during the 8 weeks.

At the conclusion of the 8 weeks, we will obtain punch biopsies from the treated lesions and from one lesion without treatment. If the patients elect, we will transition them into an open label trial with the PTH ointment including up to 1000 square cm of psoriatic lesions and monitor them for duration of effect and changes in parameters of calcium metabolism. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00007306
Study type	Interventional
Source	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 2000
Completion date	April 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01194219` - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Phase 3
Recruiting	`NCT06030076` - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed	`NCT04263610` - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy	Phase 4
Completed	`NCT02601469` - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05600036` - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05375955` - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.	Phase 2
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Not yet recruiting	`NCT05036889` - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.	N/A
Completed	`NCT04603027` - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis	Phase 2
Completed	`NCT03638258` - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis	Phase 2
Completed	`NCT02881346` - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting	`NCT02611349` - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT02251678` - Evaluate the Effect of Elimune Capsules	Phase 1
Completed	`NCT01987843` - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Terminated	`NCT01708629` - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects	Phase 3
Withdrawn	`NCT00747032` - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT01230138` - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis	Phase 2
Completed	`NCT00581100` - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis	Phase 4
Suspended	`NCT01228656` - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate	Phase 2
Completed	`NCT00540618` - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis	Phase 2